Cyclin E as a prognostic and predictive marker in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Breast cancer is a leading cause of death in women, with current treatments like chemotherapy and hormonal therapy facing challenges in patient selection.
• Traditional prognostic factors (age, lymph node status, tumor size, grade, hormone receptor status) aid risk assessment but lack precision for predicting treatment response.
• Molecular markers offer potential for refining risk stratification and personalizing adjuvant therapy decisions.

Purpose of the Study:

• To investigate the role of cyclin E as a prognostic marker and predictive factor in breast cancer management.
• To explore the potential of cyclin E as a therapeutic target for improving breast cancer treatment strategies.
• To address the limitations of current risk assessment tools in precisely stratifying patients for systemic therapies.

Main Methods:

• Review of existing literature on prognostic and predictive factors in breast cancer.
• Analysis of the role of cyclin E in breast cancer progression and response to therapy.
• Discussion of the potential clinical applications of cyclin E as a biomarker and therapeutic target.

Main Results:

• Cyclin E is identified as a significant prognostic marker and predictive factor in breast cancer.
• The study highlights the potential of molecular markers like cyclin E to improve patient stratification for adjuvant therapies.
• Cyclin E's biological underpinnings suggest its utility as a therapeutic target for specific patient subgroups.

Conclusions:

• Accurate prognostic indicators and response predictors are crucial for optimizing breast cancer treatment selection.
• Cyclin E holds promise for enhancing risk assessment and guiding therapeutic decisions in breast cancer patients.
• Targeting molecular pathways involving cyclin E could lead to more effective treatments for high-risk breast cancer.